Oral Helicobacter pylori vaccine-encapsulated acid-resistant HP55/PLGA nanoparticles promote immune protection
Oral Helicobacter pylori vaccine-encapsulated acid-resistant HP55/PLGA nanoparticles promote immune protection
复制标题
口服幽门螺杆菌疫苗封装耐酸HP55/PLGA纳米颗粒促进免疫保护
DOI：
10.1016/j.ejpb.2016.11.007
复制
发表时间：
2017-02-01
影响因子：
4.9
通讯作者：
Xing, Yingying
中科院分区：
文献类型：
--
作者：
Tan, Zhoulin;Liu, Wei;Xing, Yingying
口服疫苗的免疫原性向来较弱或无免疫原性。主要原因之一是胃肠道中的酶解和水解作用导致抗原摄取效率低下。在本研究中，研发了耐酸的HP55/聚乳酸 - 羟基乙酸共聚物（PLGA）纳米颗粒作为一种口服递送系统，以保护幽门螺杆菌重组抗原CCF免受复杂胃肠道环境的影响。这些粒径约200纳米的颗粒可控制抗原在酸性环境（pH值 （此处pH值未给出完整数值））中的释放。
Oral vaccination, is notoriously weak or nonimmunogenic. One of the major reasons is the inefficient antigen uptake caused by enzymolysis and hydrolysis in the gastrointestinal tract. In this study, acid resistant HP55/PLGA nanoparticle was developed as an oral delivery system to protect H. pylori recombinant antigen CCF against the complex gastrointestinal environment. These similar to 200 nm particles controlled the release of antigen in the acidic environment (pH